• Vaccine Name: GVAX Lung Cancer Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007461
• Type: Genetically modified cancer cells
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Host Species as Laboratory Animal Model: Human
• GM-CSF (human) gene engineering:
  • Type: Genetic modification
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: This is an autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine (NCIT_C1979). GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias.

Human Response

• Immune Response: GVAX Autologous Lung Cancer Vaccine promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function and may augment host antitumoral immunity (NCIT_C1979).
• Side Effects: For safety, cells are irradiated prior to vaccination (NCIT_C1979).